年間 6 号発行
ISSN 印刷: 1045-4403
ISSN オンライン: 2162-6502
Indexed in
Serum Levels of TGF-b and Fibronectin in Autosomal Dominant Osteopetrosis in Relation to Underlying Mutations and Well-Described Murine Counterparts
要約
The study gives a further biochemical description of two different forms of autosomal dominant osteopetrosis (ADO) in relation to murine counterparts, with special attention to osteoblast function and the recent discovery of LRP5 gene mutations in ADO I. Patients and controls were investigated for markers of bone formation and resorption at baseline and following stimulation with thyroid hormone. Moreover, four different well-described murine models of osteopetrosis were investigated.
Concerning the human forms, serum TSH levels decreased in all subjects, indicating effects on the target tissue. Osteocalcin and cross-linked collagen (NTx) were without significant differences among the groups. Significant increases in both markers were seen following stimulation. Baseline active TGF-b1 levels were increased in both types of ADO (60% in ADO I [P = 0.006]; 46% in ADO II [P = 0.001], respectively), whereas fibronectin levels were decreased in both (ADO I 58% and ADO II 63% of normal, respectively [P = 0.012 and P = 0.001]). Following treatment, levels increased temporarily in all groups. In the murine models, active TGF-b1 was significantly decreased in the tl- and ia-rat, whereas fibronectin levels were decreased in the mi-mouse, however, increased in the ia-rat.
In conclusion, both types of ADO showed the same qualitative biochemical differences compared to controls, except that OPG levels were higher in ADO I. The decreased fibronectin levels in both types and in murine models reflect decreased bone resorption; however, this may also indicate hitherto unrecognized alterations in bone formation. Biochemical differences among known syndromes related to mutations in the LRP5 gene indicate different underlying pathogenetic mechanisms.
-
Kulkarni Nalini H, Onyia Jude E, Zeng QingQiang, Tian Xioayan, Liu Min, Halladay David L, Frolik Charles A, Engler Thomas, Wei Tao, Kriauciunas Aidas, Martin T John, Sato Masahiko, Bryant Henry U, Ma Yanfei L, Orally Bioavailable GSK-3α/β Dual Inhibitor Increases Markers of Cellular Differentiation In Vitro and Bone Mass In Vivo, Journal of Bone and Mineral Research, 21, 6, 2006. Crossref
-
Bollerslev J., Wilson S.G., Dick I.M., Islam F.M.A., Ueland T., Palmer L., Devine A., Prince R.L., LRP5 gene polymorphisms predict bone mass and incident fractures in elderly Australian women, Bone, 36, 4, 2005. Crossref
-
Henriksen Kim, Neutzsky-Wulff Anita V., Bonewald Lynda F., Karsdal Morten A., Local communication on and within bone controls bone remodeling, Bone, 44, 6, 2009. Crossref
-
Henriksen Kim, Gram Jeppe, Høegh-Andersen Pernille, Jemtland Rune, Ueland Thor, Dziegiel Morten H., Schaller Sophie, Bollerslev Jens, Karsdal Morten A., Osteoclasts from Patients with Autosomal Dominant Osteopetrosis Type I Caused by a T253I Mutation in Low-Density Lipoprotein Receptor-Related Protein 5 Are Normal in Vitro, but Have Decreased Resorption Capacity in Vivo, The American Journal of Pathology, 167, 5, 2005. Crossref
-
Xie Gen-Qing, Lei Dan-Dan, He Hong-Bo, Gong Jia-Ji, Chen Chao, Chen Peng, Zhang Hong, Luo Xiang-Hang, Liao Er-Yuan, Wu Xian-Ping, Relationship between serum TGF-β1, OPG levels and osteoporotic risk in native Chinese women, Clinica Chimica Acta, 423, 2013. Crossref
-
Al-Qattan Mohammad M., AlShomer Feras, Alqahtani Abdullah, Alhadlg Ahmad, Fibronectin and Craniofacial Surgery, Annals of Plastic Surgery, 73, 6, 2014. Crossref
-
Demirel Utku, Özek Eren, Bereket Abdullah, Demirel Bilge, Topuzoğlu Ahmet, Akman İpek, Does transient hypothyroxinemia influence metabolic bone disease of prematurity?, The Journal of Maternal-Fetal & Neonatal Medicine, 26, 18, 2013. Crossref
-
Henriksen K., Bollerslev J., Everts V., Karsdal M. A., Osteoclast Activity and Subtypes as a Function of Physiology and Pathology—Implications for Future Treatments of Osteoporosis, Endocrine Reviews, 32, 1, 2011. Crossref